Protocol Ledger

NCT03617367 · Phase III · COMPLETED

Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)

Interventional Phase III clinical trial protocol NCT03617367 sponsored by Revance Therapeutics in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-09-05 Enrollment: 357 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03617367
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)357 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03617367
Protocol FieldVerified Registry Value
NCT IdentifierNCT03617367
Consolidated Lead SponsorRevance Therapeutics
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment357 participants (ACTUAL)
Registered Start Date2018-09-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03617367
Hospital Research SiteLocationSite Profile
Loma Linda University Medical CenterLoma Linda, CAOpen Hospital Dossier ->
USC Norris Comprehensive Cancer Center and Keck MedicineLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI